

Our mission
We aim to reduce the burden of disease and economic impact of dementia on patients, caregivers and society.
Goals
- To lay foundations for a 0% growth in the worldwide incidence of PD.
- To contribute to development of the first disease-modifying strategy to slow down disease progression, either in the preclinical or clinical stage for PD and specific other movement disorders.
- To generate new insights into the pathophysiology of movement disorders.
- To develop innovative biomarkers.
- To leverage AI-driven tools.
- To develop innovative treatments in both the symptomatic and disease-modifying domains.
- To improve quality of life, clinical outcomes and public health policies/clinical practices.